Rio de Janeiro, June 9, 2016. Another great day at Solaci/SBHCI 2016. Early this morning, the TCT/GI2@SOLACI session –Percutaneous Coronary Intervention– was conducted at Cristo Redentor room by Dr. Ajay Kirtane (USA), who talked about contemporary PCI. Following this event, Dr. Roxana Mehran (USA), delivered an excellent presentation on the evolution of stents and highlighted...
June 8, 2016
Rio de Janeiro – June 8, 2016. SOLACI-SBHCI 2016, the largest meeting on Interventional Cardiology in Latin America started with more than 1500 attendees. After the opening, by Congress President Marcelo Josén de Carvalho Cantarelli, we honored Dr. José Eduardo Sousa, the first to perform a coronary catheterization in Brazil, 50 years ago. After...
VII Latin American Symposium on Structural Cardiomyopathy
Do you need an update on Structural Cardiomyopathy? If so, clear your schedule from July 27 thru 29. We are hosting the 7th Latin American Symposium on Structural Cardiomyopathy, to be held at the Intercontinental Hotel in Cali, Colombia, organized by Angiografía de Occidente S.A. Featuring lectures of national and international relevance and the presence...
MitraClip: Should we prescribe it earlier?
Courtesy of Dr. Carlos Fava. Patients with severe mitral regurgitation unfit for surgery due to high surgical risk are likely to develop chronic kidney disease (CKD). There is limited information available on patients with CKD receiving MitraClip. This study analyzed patients receiving MitraClip and presenting chronic kidney disease. CKD was defined as a...
MitraClip Similar to Surgery at 5 Years
Original Title: Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation. 5 – Years Results of EVEREST II. Reference: Ted Feldman et al. J Am Coll Cardiol 2015;66:2844-54 Courtesy of Dr. Carlos Fava The MitraClip at 12 months in the EVEREST II trial showed similar outcomes to that of surgery, with improved ventricular remodeling and...
Magazines
JSHD | JOURNAL OF STRUCTURAL HEART DISEASE The scope of the Journal of Structural Heart Disease includes all adults with structural and congenital heart diseases, including imaging related to interventional therapies in structural and congenital heart disease. Principal subjects of the journal include the aortic valve, the aortic arch, the mitral valve, the left atrial...
RE-ALIGN: Dabigatran in mechanical valves. Suspended early due to more bleeding and thrombotic events.
The use of vitamin K antagonists provides excellent protection against thromboembolic complications in patients with mechanical valves, however long-term INR monitoring is needed. Dabigatran is an oral direct thrombin inhibitor which was shown to be effective in patients with atrial fibrillation. Based on these promising results this study was designed to evaluate its use in...
Incidence and clinical impact of post TAVI infective endocarditis
Original title: Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantation. Reference: Manuel Martínez-Sellés et al. EuroIntervention 2015;10-online publish-ahead-of-print February 2015. Prosthesis endocarditis is a complication with serious clinical consequences due to its high morbimortality. Infective endocarditis (IE) in TAVI has been described in few cases and, in cohort studies, it occurs within 0 to...
Impact of kidney function on TAVI outcome
Original title: Impact of chronic kidney disease on the outcome of transcatheter aortic valve implantation: results from the FRANCE 2 Registry. Reference: Atsushi Oguri, et al. EuroIntervention 2015;10:e1-9 Globally, 13% of patients present kidney failure, which has been associated to a worse evolution not only of TAVI outcomes but also of other cardiovascular intervention outcomes. Most studies, including...
Third generation percutaneous aortic valve in intermediate-risk patients
Original title: Multicenter Evaluation of a Next-Generation Balloon-Expandable Transcatheter Aortic Valve. Reference: John Webb, et al. J Am Coll Cardiol 2014;64:2235-43 Percutaneous aortic valve replacement is starting to be a reasonable alternative in patients at intermediate risk. One hundred and fifty patients who received SAPIEN 3rd generation percutaneous aortic valve implantation were analyzed prospectively. The STS score of...